<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">QUINUPRISTIN/DALFOPRISTIN</span><br/>(quin-u-pris'tin/dal'fo-pris-tin)<br/><span class="topboxtradename">Synercid<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic, streptogramin</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg vial (150 mg quinupristin/350 mg dalfopristin)</p>
<h1><a name="action">Actions</a></h1>
<p>Streptogramin (cyclic macrolide) antibiotic that is produced by various streptomyces bacteria. Active against gram-positive
         pathogens including vancomycin-resistant <i>Enterococcus faecium</i> (VREF), as well as some gram-negative anaerobes.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Indicated by clinical improvement in S&amp;S of infection. Effective against VREF resistant organisms and methicillin-resistant
         <i>Staphylococcus aureus</i> (MRSA), and <i>Streptococcus pneumoniae</i>. Synercid is not effective against <i>Pseudomonas aeruginosa</i>, <i>Enterobacteriaceae</i> or Vancomycin resistant <i>Enterococcus raecalis</i>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Serious or life-threatening infections associated with VREF bacteremia; complicated skin and skin structure infections caused
         by <i>Staphylococcus aureus</i> or <i>Streptococcus pyogenes</i>.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to quinupristin/dalfopristin or pristinamycin; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal or hepatic dysfunction; pregnancy (category B).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Vancomycin-Resistant <i>Enterococcus faecium</i>
</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 7.5 mg/kg infused over 60 min q 8 h<br/><br/><span class="indicationtitle">Complicated Skin and Skin Structure Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 7.5 mg/kg infused over 60 min q 12 h times 7 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Reconstitute a single vial by adding 5 mL D5W or sterile water for injection to yield 100 mg/mL. Gently swirl to dissolve
                  but do <small>NOT</small> shake. Allow solution to clear. Withdraw the required dose and further dilute by adding to 100 mL (central line) or 250500
                  mL (peripheral site) of D5W.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span> Flush line before &amp; after with D5W. Do <small>NOT</small> use saline. Administer over 1 h.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Saline solutions</b> and <b>Lactated Ringer's</b> solution (flush lines with D5W before infusing other drugs). <span class="incompattype">Y-site:</span> Any drugs diluted in <b>saline;</b>
<b>acyclovir,</b>
<b>aminophylline,</b>
<b>amphotericin B,</b>
<b>cefotaxime,</b>
<b>ceftazidime,</b>
<b>ceftizoxime,</b>
<b>dobutamine,</b>
<b>dopamine,</b>
<b>erythromycin lactobionate,</b>
<b>digoxin,</b>
<b>furosemide,</b>
<b>gentamicin,</b>
<b>imipenem-cilastatin,</b>
<b>insulin,</b>
<b>meropenem,</b>
<b>metronidazole,</b>
<b>piperacillin,</b>
<b>piperacillin-tazobactam,</b>
<b>ticarcillin-clavulanate.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Refrigerate unopened vials. After reconstitution solution is stable for 5 h at room temperature and 54 h refrigerated.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Headache, pain, <span class="speceff-common">myalgia, arthralgia</span>. <span class="typehead">GI:</span> Nausea, diarrhea, vomiting. <span class="typehead">Skin:</span> Rash, pruritus. <span class="typehead">Other:</span>
<span class="speceff-common">Inflammation, pain, or edema at infusion site, other infusion site reactions</span>, thrombophlebitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Inhibits CYP3A4 metabolism of <b>cyclosporine,</b>
<b>midazolam,</b>
<b>nifedipine,</b> <span class="classification">protease inhibitors</span>, <b>vincristine,</b>
<b>vinblastine,</b>
<b>docetaxel,</b>
<b>paclitaxel,</b>
<b>diazepam,</b>
<b>tacrolimus,</b>
<b>carbamazepine,</b>
<b>quinidine,</b>
<b>lidocaine,</b>
<b>disopyramide.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Moderately protein bound. <span class="typehead">Metabolism:</span> Metabolized to several active metabolites. <span class="typehead">Elimination:</span> Primarily excreted in feces (7577%). <span class="typehead">Half-Life:</span> 3 h quinupristin, 1 h dalfopristin. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of infusion site irritation; change infusion site if irritation is apparent.</li>
<li>Monitor for cutaneous reaction (e.g., pruritus/erythema of neck, face, upper body).</li>
<li>Lab tests: C&amp;S from site of infection prior to initiating therapy; WBC with differential; and liver function (especially with
            preexisting hepatic insufficiency).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report burning, itching, or pain at infusion site to physician.</li>
<li>Report any sensation of swelling of face and tongue; difficulty swallowing.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>